The European Medicines Agency (EMA) will decide today whether to approve the coronavirus vaccine from the U.S. company Johnson & Johnson. If the Amsterdam-based authority gives the green light, final approval by the EU Commission would be a mere formality, according to experience. It would be the fourth coronavirus vaccine to receive EU-wide approval, following vaccines from Biontech and Pfizer, Moderna and Astrazeneca. Against severe covid-19 disease, the vaccine has an efficacy of about 85 percent.
One advantage of Johnson & Johnson’s vector virus vaccine is that only one dose is required. It can also be stored at normal refrigerator temperatures. However, doubts have already been raised in the EU as to whether the U.S. company will be able to meet its promised delivery of 55 million doses by the end of June. According to EU sources, the first deliveries are not expected until mid-April at the earliest.
- source: orf.at/picture: aerzteblatt.de
This post has already been read 136 times!